Sharp Therapeutics Announces Non-Brokered Private Placement and Provides Operational Update

Jul 15, 2026 | Press Releases

Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – July 15, 2026) – Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) (“Sharp” or the “Company”) is pleased to announce that it is arranging a non-brokered...

Sharp Therapeutics Announces Filing of Amended and Restated Management Information Circular and New Annual Meeting Date

Jun 30, 2026 | Press Releases

Shareholders Must Recast Their Votes to be CountedPittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – June 30, 2026) – Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) (“Sharp” or the “Company”) announces that...

Sharp Therapeutics Presents New Preclinical Data Supporting Novel Small-Molecule Therapeutic Approach for Niemann-Pick Disease Type C

May 28, 2026 | Press Releases

Novel lead small molecules demonstrate substantial reduction of cholesterol accumulation in NPC patient-derived fibroblasts, with additional data supporting lysosomal health and cellular signaling NPC represents a significant new pipeline opportunity for Sharp,...

Sharp Therapeutics Corp. Announces Fourth Quarter 2025 Results, Closing of Convertible Note Offering and Adoption of Semi-Annual Reporting

Apr 17, 2026 | Press Releases

Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – April 17, 2026) – Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) (“Sharp” or the “Company”) announces the release of its annual audited...

Sharp Therapeutics Updates on ‘901 for Gaucher and GBA1 Parkinson’s and Platform Programs

Apr 10, 2026 | Press Releases

Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – April 10, 2026) – Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) (“Sharp” or the “Company”) announces that following longer-term non-GLP testing the company...